| Please check with your doctor or call 1-855-HCH-HOPE (424-4673) to find out if you qualify for any of these studies.
|
Trial #
|
Trial Sub-type
|
Title
|
|
GOG – 0263 NCI
|
Cervical Cancer, Stage I-IIA, Previously Underwent Surgery
|
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
|
|
C14008 Millennium, Inc.
|
Patients with ovarian cancer who have a treatment-free interval ≤ 12 months after platinum therapy or patients who experience persistent or recurrent disease during platinum therapy and who are candidates for treatment with weekly paclitaxel
|
Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients with Ovarian or Breast Cancer
|
|
GOG–0262 NCI
|
Histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer
|
A Randomized Phase III Trial of Every-3-weeks Paclitaxel versus Dose Dense Weekly Paclitaxel in Combination with Caboplatin Plus Concurrent and Consolidation Bevacizumab in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer
|
|
Yale University School of Medicine
|
Surgically Staged III-IV (TAH/BSO/Washings/PPAL D) or Recurrent Uterine Serous Papillary Carcinoma Patients with Measurable Disease Surgically Staged III-IV (TAH/BSO/Washings/PPAL D) or Recurrent Uterine Serous Papillary Carcinoma Patients with Measurable Disease
|
A Randomized Phase III Evaluation of Carboplatin/paclitaxel with and without Trastuzumab (Herceptin) in HER2/neu+ Patients with advanced/Recurrent Uterine Serous Papillary Carcinoma
|
|
GOG 0258

|
Advanced Endometrial Carcinoma
|
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
|
|